Review
Infectious Diseases
Antonio Mestrovic, Nikola Perkovic, Ante Tonkic, Zeljko Sundov, Marko Kumric, Josko Bozic
Summary: The increase in antibiotic resistance to H. pylori has led to a decrease in the effectiveness of eradication therapy. Tailored therapy based on sensitivity tests to antibiotics is proving to be a superior option, even as a first-line therapy. Using a susceptibility-guided strategy and PCR technology can further optimize the eradication process.
Article
Oncology
Hidehiko Takigawa, Ryo Yuge, Satoshi Masaki, Rina Otani, Hiroki Kadota, Toshikatsu Naito, Ryohei Hayashi, Yuji Urabe, Shiro Oka, Shinji Tanaka, Kazuaki Chayama, Yasuhiko Kitadai
Summary: For gastric MALT lymphoma cases that are Helicobacter pylori-negative and API2-MALT1-negative, a high rate of non-Helicobacter pylori Helicobacter infections was observed, which may have contributed to the success of eradication therapy. Therefore, eradication therapy is recommended as a first-line treatment for non-Helicobacter pylori Helicobacter-positive gastric MALT lymphoma.
Review
Medicine, General & Internal
Toshihiro Nishizawa, Munkhbayar Munkjargal, Hirotoshi Ebinuma, Osamu Toyoshima, Hidekazu Suzuki
Summary: This study reviewed 12 clinical studies and found that the vonoprazan-sitafloxacin-amoxicillin regimen is a good option for third-line Helicobacter pylori eradication treatment, although extending the treatment duration may further improve eradication rates. Confirmation of drug susceptibility before using sitafloxacin is recommended due to safety concerns related to fluoroquinolones.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Microbiology
Mariagrazia Piscione, Mariangela Mazzone, Maria Carmela Di Marcantonio, Raffaella Muraro, Gabriella Mincione
Summary: Gastric cancer is the fifth most common cancer worldwide and the third leading cause of death in developed countries, mainly caused by Helicobacter pylori which is considered a type I carcinogen. The development of gastric cancer involves a progression from gastritis to intestinal metaplasia and eventual adenocarcinoma, with steps including chronic non-atrophic gastritis triggered by H. pylori infection.
FRONTIERS IN MICROBIOLOGY
(2021)
Article
Pharmacology & Pharmacy
Qin Ma, Hancong Li, Jing Liao, Zhaolun Cai, Bo Zhang
Summary: Tailored therapy may provide a better eradication rate than empirical therapy in first-line treatment for H. pylori infection, but there may be no obvious advantage in second-line or mixed second- and third-line treatments. The results have a high level of heterogeneity and further clinical studies are warranted.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Gastroenterology & Hepatology
Youn Choi, Jun-Won Chung, Kyoung Oh Kim, Kwang An Kwon, Yoon Jae Kim, Jung Ho Kim, Ja Young Seo, Dong Kyun Park
Summary: The study compared the efficacy and safety of tailored therapy (TT) and concomitant therapy (CT) for Helicobacter pylori infection treatment. Results showed that the TT group had significantly lower treatment-related and patient-reported side effects compared to the CT group, but there were no significant differences in compliance, follow-up loss rates, and eradication success rate between the two groups.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Medicine, General & Internal
Liya Zhou, Hong Lu, Zhiqiang Song, Bin Lyu, Ye Chen, Jiyao Wang, Jun Xia, Zhan Zhao
Summary: H. pylori infection is a global health burden with high prevalence rates worldwide. This clinical practice guideline provides 12 recommendations for pharmacological treatment of H. pylori eradication, highlighting the efficacy and affordability of bismuth preparations. The recommendations are applicable to resource limited settings with similar antibiotic resistance patterns and sociological challenges.
CHINESE MEDICAL JOURNAL
(2022)
Review
Gastroenterology & Hepatology
Chun-Yan Weng, Jing-Li Xu, Shao-Peng Sun, Kai-Jie Wang, Bin Lv
Summary: H. pylori infection affects gastric mucosal functions significantly, and eradication can lead to functional recovery.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Chemistry, Multidisciplinary
A. Sofia Pinho, Catarina L. Seabra, Claudia Nunes, Salette Reis, M. Cristina Martins, Paula Parreira
Summary: Bacterial biofilms, including those formed by Helicobacter pylori, are highly resistant to antibiotics. This study found that nanostructured lipid carriers (NLC) can effectively reduce biofilm biomass and kill both biofilm and planktonic bacteria of H. pylori. Additionally, the combination of docosahexaenoic acid (DHA) and NLC showed a synergistic effect in treating H. pylori biofilms.
JOURNAL OF CONTROLLED RELEASE
(2022)
Article
Medicine, General & Internal
Xin Luo, Hui Li, Li He
Summary: The study found a correlation between age, endoscopic manifestations, and the effectiveness of H. pylori eradication therapy. Patients over 60 years old and those with multiple white and flat elevated lesions in endoscopic examination were more likely to fail H. pylori eradication with empirical quadruple therapy. On the other hand, patients with diffuse redness in endoscopic examination were more likely to succeed in H. pylori eradication therapy with empirical quadruple therapy.
FRONTIERS IN MEDICINE
(2023)
Article
Medicine, General & Internal
Gracia Ma Martin-Nunez, Isabel Cornejo-Pareja, Mercedes Clemente-Postigo, Francisco J. Tinahones, Isabel Moreno-Indias
Summary: Eradication treatment for H. pylori leads to changes in gut microbiota composition and a decrease in ghrelin levels. Specific gut bacteria have been linked to changes in ghrelin levels, suggesting a potential role in the regulation of ghrelin.
FRONTIERS IN MEDICINE
(2021)
Article
Nutrition & Dietetics
Asher Shafrir, Michal Shauly-Aharonov, Lior H. Katz, Ora Paltiel, Yishai Pickman, Zvi Ackerman
Summary: The study found that serum vitamin D levels are associated with H. pylori infection and eradication rates, with low levels of vitamin D increasing the risk of H. pylori infection. Purchase of vitamin D supplements was associated with H. pylori eradication.
Review
Medicine, General & Internal
Jun Watanabe, Masato Hamasaki, Kazuhiko Kotani
Summary: Eradication of Helicobacter pylori increases HDL-C levels and triglyceride levels, but does not significantly affect low-density lipoprotein-cholesterol levels. Further studies are needed to clarify the effects of lipid changes following H. pylori eradication on cardiovascular diseases.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Medicine, General & Internal
Chan Hyuk Park, Sun-Young Jung, Ju Won Lee, Hyo-Joon Yang, Joon Sung Kim, Beom Jin Kim, Soo In Choi, Seung In Seo, Joongyub Lee, Jae Gyu Kim
Summary: This study aimed to develop and validate operational definitions related to H. pylori eradication therapy. By analyzing nationwide registry and hospital medical records, the study proposed operational definitions for identifying individuals who received H. pylori eradication therapy and predicting successful eradication.
JOURNAL OF KOREAN MEDICAL SCIENCE
(2023)
Article
Immunology
Andrea Beer, Helmut Hudler, Maria Hader, Michael Kundi, Susanne Hudler, Valentina Taeuber, Helga Schachner, Sophie Gruber, Alexander M. Hirschl, Renate Kain, Athanasios Makristathis
Summary: The study investigated the impact of intracellular Helicobacter pylori on treatment failure, especially in the AC/PPI group. The results showed that both aiHp and resistance to clarithromycin were significant predictors of eradication failure in first-line triple therapies.
CLINICAL INFECTIOUS DISEASES
(2021)